| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
EI- Nile Co. for Pharmaceuticals and Chemical Industries Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م69.78 |
| 52 Week High | ج.م103.99 |
| 52 Week Low | ج.م37.71 |
| Beta | 0.10 |
| 11 Month Change | 4.60% |
| 3 Month Change | -4.29% |
| 1 Year Change | 74.49% |
| 33 Year Change | 87.18% |
| 5 Year Change | 298.74% |
| Change since IPO | 367.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| NIPH | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | 0% | -0.6% | 1.4% |
| 1Y | 74.5% | 28.2% | 62.5% |
Return vs Industry: NIPH exceeded the EG Pharmaceuticals industry which returned 28.2% over the past year.
Return vs Market: NIPH exceeded the EG Market which returned 62.5% over the past year.
Price Volatility
| NIPH volatility | |
|---|---|
| NIPH Average Weekly Movement | 2.3% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in EG Market | 9.0% |
| 10% least volatile stocks in EG Market | 3.3% |
Stable Share Price: NIPH has not had significant price volatility in the past 3 months.
Volatility Over Time: NIPH's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1962 | n/a | Eldin Hajjaj | www.nilepharma.com.eg |
EI- Nile Co. for Pharmaceuticals and Chemical Industries develops, produces, and sells pharmaceutical products in Egypt. The company offers tablets, capsules, ampoules, powders, gels and creams, syrups, suppositories, lotions, shampoos, ointments, mouthwashes, powder solutions, and nasal and midodrine drops. It also exports its products to the countries in the Middle East.
EI- Nile Co. for Pharmaceuticals and Chemical Industries Fundamentals Summary
| NIPH fundamental statistics | |
|---|---|
| Market cap | ج.م706.52m |
| Earnings (TTM) | ج.م163.08m |
| Revenue (TTM) | ج.م1.28b |
4.3x
P/E Ratio0.5x
P/S RatioIs NIPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NIPH income statement (TTM) | |
|---|---|
| Revenue | ج.م1.28b |
| Cost of Revenue | ج.م952.88m |
| Gross Profit | ج.م332.03m |
| Other Expenses | ج.م168.94m |
| Earnings | ج.م163.08m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 16.11 |
| Gross Margin | 25.84% |
| Net Profit Margin | 12.69% |
| Debt/Equity Ratio | 90.3% |
How did NIPH perform over the long term?
See historical performance and comparison